BIOGEN INC. 8-K

What Happened
Biogen filed a Form 8‑K on Jan 14, 2026 stating it expects its GAAP and non‑GAAP results for the quarter ended Dec 31, 2025 to include an estimated acquired in‑process research and development (IPRD), upfront and milestone expense of approximately $222 million (pre‑tax). The company estimates this charge will reduce GAAP and non‑GAAP net income per diluted share for Q4 2025 by about $1.26. Biogen notes quarter results are preliminary and subject to its financial close procedures.

Key Details

• Estimated charge: ~$222 million (pre‑tax) for Q4 2025.
• Estimated EPS impact: ~$(1.26) per diluted share (affects both GAAP and non‑GAAP EPS).
• Presentation: Biogen began showing “acquired in‑process R&D, upfront and milestone expense” as a separate line item starting Q1 2025.
• Uncertainty: Biogen does not forecast these charges due to unpredictability of timing and magnitude; final quarter results may differ.

Why It Matters
This one‑time charge reduces reported earnings for Q4 2025 by an estimated $1.26 per share and will appear in both GAAP and non‑GAAP results, so investors should expect lower reported EPS for the quarter. Because these acquired IPRD and milestone items are transaction‑driven and unpredictable, Biogen emphasizes it does not forecast them and final results remain subject to closing procedures—watch the company’s finalized earnings release and subsequent filings for confirmed figures.